In clinical studies, imiquimod 3.75% was shown to detect and treat actinic keratosis (AK) lesions across an entire sun-exposed field such as the full face or balding scalp. The aim of this study was to evaluate imiquimod 3.75% in a real-life clinical setting.
|Rivista||GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA|
|Stato di pubblicazione||Pubblicato - 2015|
- actinic keratosis